Figure 4 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial

Authors: Mario E. Lacouture, Alexander Pan, Tara Maier et al.

Publication:

Published: Unknown date

Source: Crossref

Back to Search View Original Cite This Article

Abstract

<jats:p><p>Change in biomarkers from baseline to week 4 in the total cohort. IFN, interferon; TNF, tumor necrosis factor. *, <i>P</i> < 0.05.</p></jats:p>

Keywords

pchange biomarkers from baseline week

Figure 4 from Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial

Abstract

Keywords

Related Articles

Supplementary Figure 9 from Targeting the NAD&lt;sup&gt;+&lt;/sup&gt; Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells

Supplementary Figure S4 from &lt;i&gt;SPEN&lt;/i&gt; Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities

Supplementary Data S1 from HER2 Heterogeneous Breast Cancer Models Reveal Novel Therapeutic Targets and Subclonal Dynamics during Evolution to Resistance to HER2-Targeted Therapies

Supplementary Data 2 from First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL2 in Patients with High-Grade Serous Ovarian Carcinoma

Table S11 from Association between Depression and Risk of Colorectal Cancer and Polyps: A Prospective Cohort Study from the Nurses’ Health Study II

Supplementary Figure 9 from Targeting the NAD<sup>+</sup> Salvage Pathway Blocks Metabolic Recovery and Enhances β-Lapachone Toxicity in NQO1-Expressing Glioblastoma Cells

Supplementary Figure S4 from <i>SPEN</i> Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities